Roche exercised its option to acquire Promedior for $390M upfront plus up to $1B in contingent payments tied to regulatory and commercial milestones. Lead asset PRM-151 is a recombinant pentraxin-2 in Phase 2 for idiopathic pulmonary fibrosis and myelofibrosis.